Acidul Hialuronic si HEPASCORE diagnostic inovativ al fibrozei hepatice

Similar documents
Spleen assessment by Acoustic Radiation Force Impulse Elastography (ARFI) for prediction of liver cirrhosis and portal hypertension

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Non-Invasive Testing for Liver Fibrosis

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

RELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

INHSU th International Symposium on Hepatitis Care In Substance Users

Module 1 Introduction of hepatitis

Management of Liver Diseases: A Nonhepatologist s Viewpoint

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

Hepatology For The Nonhepatologist

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.

Section: Laboratory Last Reviewed Date: May Policy No: 47 Effective Date: August 1, 2014

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

Rate scazute de raspuns virusologic rapid la pacienti infectati cronic VHC naivi din punct de vedere terapeutic

Page: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease

Electroencephalography (EEG) alteration in Autism Spectum Disorder (ASD)

Utilizare ecard in aplicaţie de raportare pentru medicii de Dializa

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

Medical Policy Non-invasive Tests for Hepatic Fibrosis

Patterns of abnormal LFTs and their differential diagnosis

Liver 102: Injury and Healing

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV

Monitoring Hepatitis C

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease

5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts

Transient elastography the state of the art

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

LIVER FUNCTION TESTS ANOMALIES IN PATIENTS WITH CHRONIC HEART FAILURE

Alternatives to Liver Biopsy for Assessing Liver Disease

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

Diagnosi e management non invasivo dell epatite cronica da HCV

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

Patterns of abnormal LFTs and their differential diagnosis

Review Article Noninvasive Biomarkers of Liver Fibrosis: An Overview

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

Abstract INTRODUCTION RAPID COMMUNICATION

Non-invasive diagnosis of hepatitis B virus-related cirrhosis

How useful are ARFI elastography cut-off values proposed by metaanalysis for predicting the significant fibrosis and compensated liver cirrhosis?

STUDIES REGARDING THE CRIOPROTECTIVE PROPRIETIES OF THE VITRIFICATION MEDIA, WITH GLYCEROL, SUCROSE AND FICOLL 70 USED IN EMBRYO CRYOPRESERVATION

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

Aspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients

NAFLD and NASH: The Not-So-New Kids on the Block

HEP DART 2017, Kona, Hawaii

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

CASES FOR DISCUSSION. Yohannes B

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

Journal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016:

Transient elastography in chronic liver diseases of other etiologies

Hepatitis C Policy Discussion

Bio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017

Proiect IDEI 2008 C Baicus

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17

Lucrări ştiinţifice Zootehnie şi Biotehnologii, vol. 40(2), (2007), Timişoara

First Journal of Homeopathic Pharmacology Published under the auspices of the Romanian Academy of Medical Sciences Volume II, N o 1, 2014

Comparison between FIB-4 Index and Fibroscan as Marker of Fibrosis in Chronic HCV Infection in Egyptian Patients

Liver fibrosis and steatosis the role of radiology. P.Prieditis P.Stradins Clinical University Hospital Riga, Latvia 9.X 2010.

Maitines septiembre de 2011 Francisco Jorquera Plaza

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France

The evaluation of liver fibrosis is a key step to manage

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Clinical cases: HIV/HCV coinfection

Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network

3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Supplementary appendix

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY.

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

FibroTest/FibroSure Scientific Publications Posters for AASLD 2012

original ArTiCle Transient elastography for the noninvasive assessment of liver fibrosis: A multicentre Canadian study

Medical Review Approaches to the Diagnosis of Liver Fibrosis

Section 3: Testing and Diagnosis of Hepatitis C

PREVALENCE OF WHITE COAT EFFECT IN TREATED HYPERTENSIVE PATIENTS FROM CARAS SEVERIN COUNTY

Hepatitis C Direct-Acting Antivirals

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Transcription:

Acidul ialuronic si EPASCRE diagnostic inovativ al fibrozei hepatice Proton Impex 2000

Topics Ce este Acidul ialuronic (A)? Structura chimica Caracteristici medicale De ce e utila masurarea A? Semnificatia clinica a A ca si marker unic Ce este EPASCRE?

Structura chimica a A Izolat in 1934 din ochiul de vaca, yalos = sticlos Polizaharid linear compus din unitati repetitive dizaharidice (Nacetylglucosamine si D-glucuronic acid) Masa moleculara variabila C NAc C NAc C NAc C NAc C NA c Mw = 2-6 10 6 -D-glucuronic acid-β-1,3-d-n-acetylglucosamine-β-1,4

Caracteristici Este distribuit ubicuitar in organism, in special in tesut conjunctiv articulatii, matrice extracelulara, cartilaj, piele, ochi Capacitate crescuta de a lega moleculele de apa (1:1000); buffer osmotic si lubrifiant pentru articulatii Concentratie scazuta in ser, timp de injumatatire 2-5 minute, este degradat de celulele endoteliale sinusoidale hepatice Concentratia serica crescuta in artrite, sepsis, mesotheliom, fibroza /ciroza hepatica Celuele endoteliale sinusoidale hepatice sunt afectate in caz de expunere la etanol sau patogeni (BV/CV) Se coreleaza foarte bine cu modificarile histopatologice hepatice (fibroza)

Semnificatie clinica A Semnificatie clinica dovedita pentru multe etiologii Etiologie Performanta Diagnostica Reference epatita Virus C (CV) epatita Virus B (BV) Alcoholic Liver Diseases (ALD) 100% NPV pentru ciroza (cutoff 50 ng/ml) alfon P et al. 90,9% sensibilitate, 98,1% specificitate pentru fibroza extensiva (cutoff 126,4 ng/ml) 82,8% sensibilitate 69% specificitate ptr. Fibroza hepatica, > Ludwig stadiul 2 (cutoff 55,5 ng/ml); concentratia serica a A creste pe masura ce distructia hepatica avanseaza Montazeri G et al. Stickel F et al. Non-Alcoholic Fatty Liver Disease (NAFLD) C282Y emochromatosis () 85% sensibilitate, 80% specificitate ptr. fibroza severa (cutoff 46,1 ng/ml) 100% sensitivitate and specificitate ptr. Ciroza (cutoff 46,5 ng/ml) la pacientii cu feritina >1000 ng/ml Suzuki A et al. Crawford DG et al.

Semnificatie Clinica a A A este cunoscut ca si marker de fibroza hepatica de ~20 ani A cel mai bun marker utilizat singur in detectia stadiilor F3/F4 Test produs de firma WAK CEMICALS JAPNIA Accuracy of A for predicting fibrosis stages in CV, alfon et al. 2005 Com. epatol. 100% NPV ptr ciroza ; cut-off 50 ng/ml A

Algorithmi de stadializare Acidul ialuronic poate fi utilizat singur sau in combinatie cu alti parametrii Name Single tests Comments Forns Index platelets, GGT, Chol, age Chol is influenced by CV genotype, low specificity for signifcant fibrosis APRI AST, platelets Low sensitivity for significant fibrosis, but acceptable, easy and cheap Fibrotest GGT, haptoglobulin, tbil, alpha-2- macroglobulin, ApoA, age, sex Commercialised by Biopredictive (France) and by far most used score, massive investigated with CV patients Fibrospect A, TIMP-1, alpha-2-macroglobulin Good differentiation between F2 and F4 ELF A, PIINP, TIMP-1, age Good staging published, commercialised by Siemens and IQUR (UK) Fibrometer platelets, A, alpha-2-macroglobulin, AST, Urea, prothrombin index Good staging published, commercialised by Biolivescale (France) epascore tbil, GGT, A, alpha-2-macroglobulin, age, sex Good staging published, mostly evaluated with CV patients SASTA A, Alb, AST nly evaluated for IV/CV coinfected patients

Protocol evaluare fibroza

EPASCRE Dezvoltat de un grup de cercetatori Australieni in 2005 Adams et al. 4 teste biochimice, varsta si sexul pacient : GGT, Bilirubina, alpha 2 Macroglobulina, Acid ialuronic Testele se pot efectua automat pe un singur analizor Algorithm de calcul gratuit poate fi folosit de orice laborator** Validat de Autoritatea Nationala pentru Sanatate in Franta si utilizat de Quest Diagnostics in SUA Performante foarte bune, comparabile cu alti algoritmi

Alegerea testelor Bilirubina creste pe masura ce fibroza avanseaza ca rezultat al excretiei hepatice reduse GGT este corelata cu fibroza hepatica la pacientii infectati cu hepatita B si C. A fibroza mareste productia de A de catre celulele stelate hepatice si diminueaza clerance-ul in celulele endoteliale sinusoidale Alpha 2-Macroglobulina este un inhibitor de proteaza a carui concentratie creste in momentul activarii celulelor stelate si a evolutiei fibrozei

Algoritm EPASCRE EPASCRE = y / ( 1 + y ) * Un program informatic pentru calcul automat al scorului va fi pus la dispozitia laboratoarelor care vor utiliza acest algoritm.

Interpretare S 0,5 - Fibroza semnificativa ( F2 ) ( 92% specificitate si 67% sensitivitate, PPV 87% ) S < 0,5 - Absenta fibroza avansata ( F3 ) ( 81% specificitate si 95% sensitivitate ) S < 0,84- Exclude Ciroza epatica ( 84% specificitate si 71% sensitivitate, NPV 94% )

EPASCRE vs Fibroza cut-off 0,84 cut-off 0,5 epascore : An accurate Validated Predictor of liver Fibrosis in Chronic epatitis C Infection Adams et Al. 2005

Valoare diagnostica S 0,5 pacientul poate fi candidat ptr.terapie antivirala fara a se efectua o biopsie ; S < 0,5 excluderea fibrozei avansate poate fi utila ca si prognostic pentru pacientii care nu doresc biopsie sau pentru pacientii in varsta la care e improbabil sa apara o morbiditate / mortalitate corelata afectarii hepatice in absenta fibrozei avansate. S > 0.84 specific 84-89% pentru prezenta cirozei, poate elimina necesitatea biopsiei hepatice la pacientii la care se suspecteaza o ciroza oculta sau sa ghideze managementul deciziilor privind screening-ul variceal sau de carcinom, precum si monitorizarea pacientului

epascore Automation of the epascore and validation as a biochemical index Guéchot et al. Clin Chim Acta 2010

Valoare diagnostica si cost Contribution of the ELFG Test in Algorithms of Noninvasive Markers towards the Diagnosis of Significant Fibrosis in Chronic epatitis C *Jean Pierre Zarski et al., March 21, 2013 *** Test ELFG utilizat cand unul din testele de prima intentie nu ofera rezultate concludente

Numar de biopsii evitate

Valoare diagnostica validata Retrospective and recent independent prospective studies have shown that the four most validated non-invasive methods, Fibrotest, Fibrometer, epascore and Fibroscan have similar performances for the diagnosis of significant fibrosis (METAVIR F>2) in CC. These methods have been recently approved after an independent systematic review by the French National Authority for ealth for the first line assessment of fibrosis in naıve patients with CC...

Cost redus

Corelatia cu alte metode Conclusions:. interpretable Fibroscan, Fibrometer, and epascore perform best and similarly for diagnosis of significant fibrosis and cirrhosis. (1) Les méthodes non invasives les plus utilisées en France seraient FIBRSCAN et FIBRTEST et de façon moindre epascore, FIBRMETRE et l ARFI. (2) (1) Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS CEP-23 study Jean-Pierre Zarski et al. 2011 (2) Evaluation des méthodes non invasives de mesure de la fibrose hépatique au cours de l hépatite B Chronique aute Authorite de Sante France 2013

Concluzii Acidul ialuronic determinat singur poate discrimina intre ciroza si fibroza avansata epascore este utilizat cu succes in ghidare deciziilor terapeutice avand aceeasi valoare diagnostica ca si testele recunoscute in acest moment in Romania

Va multumesc pentru atentie! Acest produs va este oferit de : PRTN IMPEX 2000 SRL no. 9, Mugur Mugurel str.,sector 3 Bucuresti, 031227 www.proton.com.ro